Abstract: A method and composition for treating a subject having a difficult to treat tumor is described. A TRAF3IP2 silencer is administered to the subject, preferably together with other synergistic medication such as chemotherapy, immunotherapies or other anticancer medication, that given alone are less or not successful for treating this special tumor, to increase relapse free survival. The TRAF3IP2 silencer in conjunction with other synergistic medication can additionally be used to effectively treat or prevent metastasis in a subject having an otherwise difficult to treat tumor.

Abstract: A composition comprising isolated vascular-associated naturally pluripotent stem cells (vaPS), is disclosed, as well as method of treating defects using such composition, wherein said vaPS are capable of differentiating into somatic cells of all three germ layers under the guidance of the respective microenvironment.

Abstract: Novel engineered oncolytic protoparvoviruses are described to be used in cancer therapy. The engineered protoparvoviruses contain at least one deletion in the untranslated region and a silencer sequence that remains stably integrated into the viral genome during extensive virus propagation. The novel viruses can be used for the silencing of relevant cancer-related genes, providing to the virus a new anticancer mechanism of action.

Abstract: Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.

Abstract: Methods are provided for treatment of cancer in a subject's body by intraluminal delivery of oncolytic viruses through a balloon catheter or alternative mechanism inserted in a blood vessel or duct leading to a target site of the cancer tissue, or for somatic cell gene therapy of single defective gene-caused other diseases or disorders by similar intraluminal delivery of non-oncolytic viruses to a target site of affected tissue and cells of the disease or disorder, wherein during delivery of the oncolytic or non-oncolytic virus, the designated vessel or duct is selectively occluded at both ends of the target site by two spaced-apart inflated balloons of the catheter to block perfusion therethrough and allow control of the volume of virus delivered to the target site so as to increase concentration and pressure of the virus thereat sufficient to enable viral penetration of an endothelial barrier of the vessel or duct without compromise thereof and into diseased cells in the vicinity of the target site toward a

Abstract: Methods are provided for treatment of cancer in a subject's body by intraluminal delivery of oncolytic viruses through a balloon catheter or alternative mechanism inserted in a blood vessel or duct leading to a target site of the cancer tissue, or for somatic cell gene therapy of single defective gene-caused other diseases or disorders by similar intraluminal delivery of non-oncolytic viruses to a target site of affected tissue and cells of the disease or disorder, wherein during delivery of the oncolytic or non-oncolytic virus, the designated vessel or duct is selectively occluded at both ends of the target site by two spaced-apart inflated balloons of the catheter to block perfusion therethrough and allow control of the volume of virus delivered to the target site so as to increase concentration and pressure of the virus thereat sufficient to enable viral penetration of an endothelial barrier of the vessel or duct without compromise thereof and into diseased cells in the vicinity of the target site toward a

Abstract: A self-replicating RNA for inducing somatic differentiation of unmodified adult stem cells is described. Methods of differentiating unmodified adult stem cells into functional beta-like cells are also described, as well as compositions, tissues and devices containing such cells. The method requires inducing sequential expression of PDX1 before NGN3, and NGN3 before MAFA in these stem cells to form reprogrammed beta-cells. Self-replicating RNAs are provided and introduced into the adult stem cells to induce the sequential expression. Methods of treating diabetes are also provided, comprising obtaining stem cells, preferably from a patient with diabetes, inducing sequential expression of PDX1>NGN3>MAFA, in said stem cells to form reprogrammed beta-cells, and introducing said reprogrammed beta-cells into a pancreas of said patient.

Abstract: Methods of differentiating unmodified adult stem cells into functional beta-like cells are provided, as well as compositions, tissues and devices containing such cells. The method requires inducing sequential expression of PDX1, NGN3, and MAFA in these stem cells to form reprogrammed beta cells. Methods of treating diabetes are also provided, comprising obtaining stem cells, preferably from a patient with diabetes, inducing sequential expression of PDX1, NGN3, and MAFA, in said stem cells to form reprogrammed beta cells, and introducing said reprogrammed beta cells into a pancreas of said patient. Alternatively, it may be possible to inject such cells systemically, if the cells are targeted for the pancreas. In yet another embodiment, the reprogrammed beta cells are placed into an artificial pancreas that is surgically placed or injected into the patient.

Abstract: This invention relates generally to compositions and methods for treatment of pancreatic cancer. The present invention relates more particularly to use of JNK inhibition together with administration of TRAIL to selectively suppress cancer stem cells.

Abstract: Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.

Abstract: Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.

Abstract: A catheter has a proximal portion of relatively larger central lumen diameter and outer diameter, and a distal portion of relatively smaller central lumen diameter and outer diameter, the two portions being integral with one another so that cells delivered into the central lumen of the proximal portion will flow through and exit the central lumen of the distal portion, encountering a constriction at the junction of the two portions, for infusion into body tissue at a predetermined target site when the catheter is inserted into a designated natural body vessel or duct leading to the target site. The cells are delivered in a fluid under pressure through a central lumen of the catheter to exit distally from the lumen at the target site, and meander of exiting fluid pressure from a predetermined value is minimized by adjusting the fluid pressure at the point of entry into the catheter's central lumen accordingly.

Abstract: Methods are provided for treatment of cancer in a subject's body by intraluminal delivery of oncolytic viruses through a balloon catheter or alternative mechanism inserted in a blood vessel or duct leading to a target site of the cancer tissue, or for somatic cell gene therapy of single defective gene-caused other diseases or disorders by similar intraluminal delivery of non-oncolytic viruses to a target site of affected tissue and cells of the disease or disorder, wherein during delivery of the oncolytic or non-oncolytic virus, the designated vessel or duct is selectively occluded at both ends of the target site by two spaced-apart inflated balloons of the catheter to block perfusion therethrough and allow control of the volume of virus delivered to the target site so as to increase concentration and pressure of the virus thereat sufficient to enable viral penetration of an endothelial barrier of the vessel or duct without compromise thereof and into diseased cells in the vicinity of the target site toward a

Abstract: This invention relates generally to compositions and methods for treatment of pancreatic cancer. The present invention relates more particularly to use of JNK inhibition together with administration of TRAIL to selectively suppress cancer stem cells.

Abstract: Methods for the extraction and processing of umbilical stem cells for therapeutic and diagnostic purposes are disclosed. The methods provide high regenerative cell numbers and high cell viability. Further, the methods do not require culturing the cells in serum or growth factors. Certain aspects of the present invention concern methods of processing tissue for use in regenerative medicine. In another aspect of the invention, the tissue is processed and the resulting cell preparation administered within one and the same medical procedure.

Abstract: Methods, apparatus and compositions are provided for treatment of cancer of a selected organ by intraluminal delivery of oncolytic agents through a blood vessel or duct leading to the cancer tissue. During the time the oncolytic agents are being applied to the targeted tissue downstream, the designated vessel or duct can be selectively occluded to increase concentration and pressure of the applied agents at the target site. Oncolytic compositions including oncolytic viruses formulated with delivery visualization markers are provided.

Abstract: This document provides prophylactic methods for reducing cancer metastasis by targeting LCN2, MMP9, and CX-CR4.

Abstract: A catheter has a proximal portion of relatively larger central lumen diameter and outer diameter, and a distal portion of relatively smaller central lumen diameter and outer diameter, the two portions being integral with one another so that cells delivered into the central lumen of the proximal portion will flow through and exit the central lumen of the distal portion, encountering a constriction at the junction of the two portions, for infusion into body tissue at a predetermined target site when the catheter is inserted into a designated natural body vessel or duct leading to the target site. The cells are delivered in a fluid under pressure through a central lumen of the catheter to exit distally from the lumen at the target site, and meander of exiting fluid pressure from a predetermined value is minimized by adjusting the fluid pressure at the point of entry into the catheter's central lumen accordingly.

Abstract: Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.

Abstract: This document describes methods and an apparatus for recovery of a cell-enriched matrix and cells (e.g., regenerative cells) from a tissue sample. In some embodiments, at least two rounds of acceleration and deceleration are performed.